Revenue segments as reported by the company.

Medical Devices

Specialty Pharmaceuticals

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Royalty expense

Amortization expense

Intangible asset impairment charges

Contingent consideration net expense (benefit)

Restructuring net charges (credits)

Litigation-related net charges (credits)

Gain on disposal of businesses and assets

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Boston Scientific

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment consists of technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979, and is headquartered in Marlborough, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Boston Scientific reports solid Q4 performance and eyes global growth

Boston Scientific's Q4 performance was solid, with growth across regions and business units.
Challenges include potential sales growth hurdles in Q1 2023 and headwinds from tough comps and market adjustments.
Opportunities lie in continued momentum in key business units, successful product launches, and global growth prospects.
The company remains focused on sustaining growth, expanding margins, and delivering double-digit adjusted EPS growth.

Boston Scientific surpasses Q1 expectations, eyes growth through Farapulse

Boston Scientific's Q1 '23 earnings call showcased strong performance, with exceeding revenue expectations and solid organic sales growth. The company's strategic focus on high-growth M&A, resolving supply constraints for Farapulse, and capital allocation priorities position it well for future growth. Challenges include potential earnings dilutive deals and addressing free cash flow conversion challenges.

Boston Scientific surpasses Q2 expectations, eyes margin expansion and innovation

Boston Scientific delivered a strong Q2 '23 performance, exceeding expectations with robust sales growth and improved adjusted EPS, driven by strong performance across key regions and business segments.
While facing challenges such as inflation impact and market dynamics, the company remains focused on opportunities for margin expansion, product innovation, and strategic acquisitions to drive future growth.
With a positive outlook for the coronary business, upcoming product launches, and a commitment to operational excellence, Boston Scientific aims to maintain its competitive edge and capitalize on market opportunities.
Anticipated results from trials, market potential for new products, and a focus on sustainable growth strategies position Boston Scientific for continued success and market leadership in the healthcare sector.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities ahead

Boston Scientific's Q3 2023 results exceeded expectations, with strong performance across regions and business units.
The company raised full-year guidance, expecting organic revenue growth of approximately 11% and adjusted EPS range of $1.99 to $2.02.
Challenges in the Neuromodulation business and cost impacts are being addressed for future improvement.
Opportunities lie in acquisitions, FDA approvals, and strategic commercial initiatives for growth and margin expansion.

Boston Scientific (BSX) exceeds Q4 expectations, eyes growth opportunities

Boston Scientific (BSX) reported impressive Q4 2023 results, exceeding sales and EPS guidance.
The company showcased strong regional growth, highlighted key products, and outlined solid 2024 outlook.
While facing challenges like delayed product launches and market disruptions, BSX remains focused on growth opportunities.
Strategic acquisitions and margin improvement initiatives position Boston Scientific for continued success in the future.

Boston Scientific beats Q1 expectations, eyes growth in key markets

Boston Scientific delivered strong Q1 results, exceeding expectations and showcasing growth across key regions and business units.
While facing challenges like inventory charges, the company is focused on leveraging opportunities in expanding product indications and enhancing capabilities.
With raised full-year guidance and a focus on innovation and market expansion, Boston Scientific is poised for continued growth and success in 2024.

Boston Scientific (BSX) reports stellar Q2 results and eyes sustained growth

Boston Scientific's Q2 2024 performance exceeded expectations, showcasing strong financial results and regional sales growth across key markets.
The company's strategic strengths lie in diversified business units, innovative products like FARAPULSE, and strategic acquisitions like Silk Road Medical.
While challenges exist in adoption metrics and margin expansion, BSX's focus on reinvestment and growth opportunities position it well for sustained success.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities in Asia

Boston Scientific's Q3 performance exceeded expectations, driven by strong sales growth and increased adjusted EPS.
The company's focus on innovation and strategic investments in key business units like Cardiology and Neuromodulation bode well for future growth.
Despite challenges in China and the need to deliver on growth targets, Boston Scientific remains confident in its ability to sustain top-tier financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Hill-Rom Hlds

HRC vs. BSX: Which Stock Is the Better Value Option?

HRC or BSX: Which Is the Better Value Stock Right Now?

Boston Scientific preliminarily announced disappointing fourth-quarter sales on Tuesday, sending BSX stock into a tailspin. The biggest shortfall came from cardiac rhythm management.

Leading Medtech Stock Dives After Preliminary Sales Report Disappoints

Shares of Boston Scientific Corp. BSX, -0.44% dropped 6.3% in premarket trading Tuesday, after the medical technology company provided a fourth-quarter sales outlook that was below expectations.

Boston Scientific's stock falls after downbeat sales update

Boston Scientific (NYSE: BSX) spent $2.9 billion on selling, general & administrative (SG&A) expense in 2016, and the figure increased to $3.6 billion in 2018, driven by the growth in sales, and launch of new products. As a percentage of revenue, SG&A declined from 39% in 2016 to 36% in 2018.

How Much Does Boston Scientific Spend On SG&A?

Merck

Though the market is at all-time highs, not every stock can say the same. These three stocks to buy should reach new peaks in 2020.

3 Stocks to Buy That Will Hit New All-Time Highs in 2020

Abbott Labs

Abbott and Boston Scientific are both engaged in the medical devices business. Abbott generates 3x the revenue when compared to Boston Scientific.

How Does Abbott’s Revenue And Other Key Metrics Compare With That of Boston Scientific?

Athenex

ConforMIS

Dare Bioscience

Athenex Mixed Results, Boston Scientific Approval, And Other News: The Good, Bad, And Ugly Of Biopharma

Boston Scientific (BSX) is optimistic about sustaining the growth momentum on recent positive developments.

Boston Scientific Hits New 52-Week High: What's Driving it?

Boston Scientific's (BSX) EXALT Model D single-use duodenoscope gets clearance from the FDA for use in ERCP procedures.

Boston Scientific's First Single-Use Duodenoscope Gets FDA Nod

Amgen

UnitedHealth Group

The year-end success of the healthcare sector has led to several strong stocks to buy. Here are three of the best healthcare stocks to buy.

3 Healthcare Stocks to Buy Before the End of 2019

Medtronic

Boston Scientific and Medtronic are both engaged in the medical devices business. Medtronic generates 3x the revenue when compared to Boston Scientific.

How Does Boston Scientific’s Revenue And Other Key Metrics Compare With That of Medtronic?

Boston Scientific Corporation (BSX) Management presents at Piper Jaffray 31st Annual Healthcare Conference (Transcript)

These study results are expected to be a major breakthrough for Boston Scientific's (BSX) Cardiovascular segment.

Boston Scientific's Watchman Implant Study Results Encourage

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?

Boston Scientific (BSX) Up 4.5% Since Last Earnings Report: Can It Continue?

Boston Scientific’s (NYSE: BSX) fair price estimate based on expected fiscal 2020 earnings is $44, according to Trefis estimates. This is slightly above the current market price of around $42.

What’s Boston Scientific’s Fair Stock Price Estimate Based On Expected 2020 Earnings?

Boston Scientific (BSX) issues an urgent field safety notice for AngioJet Ultra consoles.

Safety Notice Issued by Boston Scientific (BSX) for AngioJet

Boston Scientific Corp (BSX) Presents at Stifel Healthcare Broker Conference Call - (Transcript)

Boston Scientific Corporation (NYSE: BSX) are up 8.5% since the company reported third-quarter earnings in late October.

Large Option Traders Betting Boston Scientific Has Run Out Of Steam

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

CareDx

Gilead Sciences

For the first time in years, for 2019 active managers are outperforming index funds, and that should be a loud wake-up call to passive investors.

Raymond James 4 Analyst Favorite Health Care Picks With Huge Upside Potential

Boston Scientific (BSX) saw a big move last session, as its shares jumped 5% on the day, amid huge volumes.

Boston Scientific (BSX) Catches Eye: Stock Jumps 5%

Boston Scientific Corporation (BSX) CEO Michael Mahoney on Q3 2019 Results - Earnings Call Transcript

Rollins

Winnebago

Earnings continued to separate winners from losers even as indexes moved only modestly higher.

Why Winnebago Industries, Rollins, and Boston Scientific Jumped Today

Boston Scientific (BSX) is making an all-out effort to solidify its core businesses and invest in the new technologies as well as the global markets. This reflects on the sales uptick in Q3.

Boston Scientific (BSX) Beats on Q3 Earnings, Tapers EPS View

Boston Scientific (BSX) delivered earnings and revenue surprises of 2.63% and 2.36%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Boston Scientific (BSX) Q3 Earnings and Revenues Beat Estimates

Thermo Fisher Scientific

Boston Scientific earnings and Thermo Fisher earnings beat views modestly Wednesday. Both medtech stocks rose.

News for Boston Scientific Stock (BSX)